Crinetics Pharmaceuticals Inc (CRNX): A Case For Going Higher

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

Crinetics Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $39.46 and fluctuated between $39.49 as its day high and $38.39 as its day low. The current market capitalization of Crinetics Pharmaceuticals Inc is $2.64B. A total of 0.51 million shares were traded on the day, compared to an average of 0.64 shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, CRNX has seen 0 BUY and 1 SELL insider trades, representing the acquisition of 0 and the disposition of 3,000 shares. Over the last 12 months, there were 22 BUYs and 18 SELLs from insiders. Insiders purchased 520,950 shares during that period but sold 373,400.

In the most recent transaction, Betz Stephen F. sold 3,000 shares of CRNX for 37.26 per share on Jan 25. After the transaction, the Chief Scientific Officer now owns 73,298 company shares. In a previous transaction on Jan 10, Betz Stephen F. sold 3,000 shares at 37.65 per share. CRNX shares that Chief Scientific Officer owns now total 76,298.

Among the insiders who sold shares, Pizzuti Dana disposed of 14,375 shares on Jan 03 at a per-share price of $35.00. This resulted in the Chief Med and Dev Officer holding 5,911 shares of CRNX after the transaction. In another insider transaction, Wilson Marc sold 10,000 shares at $35.47 per share on Jan 02. Company shares held by the CFO now total 96,055.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for CRNX in the last 3 months, the mean price target is $48.00 with high estimates of $62.00 and low estimates of $35.00. In terms of 52-week highs and lows, CRNX has a high of $39.19 and a low of $15.23.

As of this writing, CRNX has an earnings estimate of -$0.86 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.67 per share and a lower estimate of -$1.07. The company reported an EPS of -$0.94 in the last quarter, which was -9.30% lower than expectations of -$0.86.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. CRNX’s latest balance sheet shows that the firm has $333.71M in Cash & Short Term Investments as of fiscal 2021. There were $3.07M in debt and $15.99M in liabilities at the time. Its Book Value Per Share was $8.21, while its Total Shareholder’s Equity was $331.94M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRNX is Buy with a score of 4.83.

Most Popular

Related Posts